Abstract:Abstract Background Microglia have been implicated in the pathophysiology of Alzheimer’s disease (AD) for over 100 years, and substantial progress has been made in characterizing microglial heterogeneities and biology, including disease‐associated microglia (or DAM, amyloid‐pathology related, neuro‐protective), tau microglia (tau‐pathology related), and inflammatory microglia (neuro‐toxic). However, the crucial next step knowing how to apply these findings to develop new treatments for AD, through uncovering the functional roles and molecular drivers of each microglial subtype, has not yet been accomplished. Method In this study, we conducted single‐cell RNA‐sequencing data integration analyses of ∼0.8 million cells/nuclei by leveraging frozen brain samples from AD subjects across different brain regions from The Alzheimer’s Cell Atlas ( https://taca.lerner.ccf.org/ ) using a deep learning analytic approach. We annotated three microglial subtypes (including DAM, tau, and inflammatory microglia) using well‐established marker genes and then used a human protein‐protein interactome network‐based approach to identify potential molecular drivers of different microglial subtypes across the spectrum of AD. We also applied transition gene network analysis to characterize microglial subtype transition from non‐disease associated to disease‐associated stages at transcriptomic levels. Result Via trajectory analysis we pinpointed the existence of three microglial subtypes across AD progression. We also identified that tau microglia were significantly associated with synaptic processes. Compared to DAM, upregulated genes within inflammatory microglia were more significantly enriched within key immune pathways (e.g., NF‐kappa B and toll‐like receptor signaling pathways). In addition, transition gene networks of inflammatory microglia and DAM were found to contain potential AD pathobiology regulators (e.g., SYK, LYN, IRF8, and CSF1R) and genetic risk genes (including INPP5D, PICALM, and MEF2A). We further conducted network‐based drug repurposing prediction by simultaneously activating DAM while inhibiting inflammatory microglia, which indicated that several predicted repurposable drugs (i.e., fluticasone and mometasone) are significantly associated with reduced risk of AD in large patient databases. Conclusion This study identifies potential underlying mechanisms of microglial subtypes involved in human AD brains, leading to potential drug targets for future development of microglia‐targeted therapies for AD.

A Network‐based Deep Learning Framework Translates GWAS and Multi‐Omics Findings to Pathobiology and Drug Repurposing for Alzheimer’s Disease

Interpretable deep learning translation of GWAS and multi-omics findings to identify pathobiology and drug repurposing in Alzheimer's disease

Identifying Shared Diagnostic Genes and Mechanisms in Vascular Dementia and Alzheimer's Disease Via Bioinformatics and Machine Learning

Artificial intelligence framework identifies candidate targets for drug repurposing in Alzheimer's disease

Discovery of disease‐associated, tau, and inflammatory microglial subpopulations and molecular drivers in Alzheimer’s disease using network‐based deep learning integration of human brain single‐cell RNA‐sequencing data

AI-DrugNet: A network-based deep learning model for drug repurposing and combination therapy in neurological disorders

An integrated brain-specific network identifies genes associated with neuropathologic and clinical traits of Alzheimer’s disease

Identifying risk genes and therapeutics for Alzheimer’s disease through integration multi‐omics and drug‐perturbation signatures

An Integrated Brain-Specific Network Identifies Genes Associated with Neuropathologic and Clinical Traits of Alzheimer's Disease.

Network Proximity-based computational pipeline identifies drug candidates for different pathological stages of Alzheimer's disease

Identification of novel drug targets for Alzheimer’s disease by integrating genetics and proteomes from brain and blood

Genome-wide prediction and integrative functional characterization of Alzheimer’s disease-associated genes

G-Protein Signaling in Alzheimer's Disease: Spatial Expression Validation of Semi-Supervised Deep Learning Based Computational Framework

Identification of Novel Drug Targets for Alzheimer's Disease by Integrating Genetics and Proteomes from Brain and Blood.

Harnessing endophenotypes and network medicine for Alzheimer's drug repurposing

Identification of Novel Immune-Relevant Drug Target Genes for Alzheimer's Disease by Combining Ontology Inference with Network Analysis.

Computational Drug Repurposing for Alzheimer’s Disease Using Risk Genes From GWAS and Single-Cell RNA Sequencing Studies

Deep Post-Gwas Analysis Identifies Potential Risk Genes and Risk Variants for Alzheimer’s Disease, Providing New Insights into Its Disease Mechanisms

Genome wide association neural networks (GWANN) identify genes linked to family history of Alzheimer’s disease

Deep learning methods improve polygenic risk analysis and prediction for Alzheimer’s disease

Brain-wide Genome-Wide Colocalization Study for Integrating Genetics, Transcriptomics and Brain Morphometry in Alzheimer's Disease